Figure 3.
Depletion of FAP+ stromal cells and loss of skeletal muscle mass. (A) BAC transgenic mice and littermates were treated with DTX for 2 d, and total body weight and food intake were measured each day during the ensuing 3 wk. Arrows indicate when DTX was given, and the red highlighting shows the period over which it was being administered. (B) The mass of the quadriceps muscles from BAC transgenic mice and littermates was measured on days 3 and 22 after DTX treatment. (C) The mean cross-sectional area of the fibers of the quadriceps muscles from BAC transgenic mice and littermates taken 22 d after DTX treatment was measured, after fibers were delineated by staining with antibody to the basal lamina. Bar, 100 µm. (D) The number of FAP+ cells and the level of FAP mRNA in quadriceps muscles of BAC transgenic mice as a percentage of littermates were measured 3 and 22 d after DTX treatment. (E) The mRNA levels for atrogin-1, MuRF1, Fst, Lama2, and Mstn in quadriceps muscles of BAC transgenic mice and littermates were measured 3 and 22 d after DTX treatment. (F) The levels of Fst protein in quadriceps muscles of BAC transgenic mice and littermates were measured by immunoblot analysis 10 d after DTX treatment. (G) Quadriceps muscle from a normal mouse was stained with antibodies to FAP and laminin and assessed by confocal microscopy. (H) The FAP+ subset of enzymatically dissociated cells from quadriceps muscle were sort purified, and the mRNA levels of Lama2, Fst288, and Fst315 in FAP+ cells were determined by RNA-Seq. (I) The indicated subsets of enzymatically dissociated cells from quadriceps muscle were sort purified, and the mRNA levels of Fst, Lama2, Mstn, and FAP were determined by qRT-PCR. Error bars represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data are representative of more than three independent analyses (n ≥ 3; A) or are representative of two independent analyses (n ≥ 5; B–F).